Lineage Cell Therapeutics, Inc.

AMEX:LCTX

Biotechnology

Healthcare
$0.84 -2.80%

-$0.04 today

Market cap
$212.10M
Beta
1.51
P/E (TTM)
-4.6
EPS (TTM)
-$0.26
52W Low $0.85High $2.09

Volume 1.22M

Average 1.19M

LCTX Net Margin

Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.

Lineage Cell Therapeutics, Inc.AMEX: LCTX

Net Margin · Q1 FY2026 · quarter ended Mar 2026

Net margin narrows to -279.0%

Net margin was -279.0% in Q1 FY2026, down 3.4 pp from a year earlier. On a trailing-twelve-month basis it was -434.4%, down 264.9 pp year over year. Over 3 fiscal years it narrowed by 257.8 pp.

Context

  • Net margin widened in 1 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

What to watch

Whether net margin reaches the consensus estimate from 4 analysts of -113.0% for the fiscal year ending Dec 2026, up from -436.5% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-279.0%-291.8 pp QoQ
Last fiscal yearDec 2025
-436.5%-240.6 pp YoY
LTMMar 2026
-434.4%-264.9 pp YoY
Net Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-3.4 pp+906.4 pp+909.8 pp
1 year-240.6 pp+323.4 pp+564.0 pp
3 years-257.8 pp+486.2 pp+744.0 pp
5 years+490.2 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Margin history

Percent of revenue · from the income statement

Latest · FY2025
-436.5%
Year-over-year change
-240.6pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Margin vs competitors

How LCTX compares with its peers on the latest reported figures

  • LCTX's LTM Mar 2026 net margin of -434.4% is the lowest of the 4 companies compared; the peer median is -47.8%.
  • Its year-over-year change of -264.9 pp is the lowest of 4, against a peer median of +546.1 pp.
  • Over three fiscal years its change of -257.8 pp compares with a peer median of +1043.9 pp.
LCTX Competitors Peer median
Net Margin for LCTX and competitors
Company Period LTM level YoY 3-year change
IPSCCentury Therapeutics, Inc.FY2025-8.8% +1912.1 pp+2509.6 pp
MESOMesoblast LimitedLTM Jun 2026-47.8% +546.1 pp+1043.9 pp
CELUCelularity Inc.LTM Dec 2025-345.4% -238.7 pp-424.7 pp
LCTXLineage Cell Therapeutics, Inc.LTM Mar 2026-434.4% -264.9 pp-257.8 pp
Peer median (excluding LCTX) -47.8%+546.1 pp+1043.9 pp

Competitors are the stored peer set for LCTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue3.9M14.7M8.95M9.5M14.56M
Cost of Revenue1.43M728K671K334K845K
Gross Profit2.47M13.98M8.27M9.17M13.71M
Gross Margin63.4%95.0%92.5%96.5%94.2%
Research & Development33.91M13.99M15.71M12.47M17.73M
Selling, General & Admin18.21M22.51M17.3M18.17M18.46M
Operating Expenses51.68M36.5M33.01M30.64M35.49M
Depreciation & Amortization873K727K692K609K699K
EBITDA(42.4M)(25.09M)(22.59M)(17.97M)(67.95M)
EBITDA Margin-1088.2%-170.6%-252.5%-189.2%-466.8%
Operating Income(49.21M)(22.52M)(24.73M)(21.48M)(21.78M)
Operating Margin-1263.1%-153.2%-276.5%-226.1%-149.6%
Interest Income2K829K1.63M1.72M1.69M
Interest Expense00000
Other Income / Expenses5.94M(3.29M)1.45M2.9M(46.87M)
Income Before Tax(43.27M)(25.81M)(23.28M)(18.58M)(68.65M)
Pre-Tax Margin-1110.6%-175.6%-260.3%-195.6%-471.6%
Income Tax Expense0541K(1.8M)0(5.11M)
Net Income(43.02M)(26.27M)(21.49M)(18.61M)(63.53M)
Net Margin-1104.2%-178.7%-240.2%-195.9%-436.5%
EPS (Basic)(0.26)(0.15)(0.12)(0.09)(0.28)
EPS (Diluted)(0.26)(0.15)(0.12)(0.09)(0.28)
Weighted Avg Shares164.5M169.79M172.66M200.19M230.12M
Weighted Avg Shares (Diluted)164.5M169.79M172.66M200.19M230.12M

Lineage Cell Therapeutics, Inc.

AMEX:LCTX

Intrinsic Alpha fair value

Locked

Current Price

$0.84

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.